Equities

Wanbury Ltd

WANBURY:NSI

Wanbury Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)278.79
  • Today's Change12.78 / 4.80%
  • Shares traded169.98k
  • 1 Year change+362.72%
  • Beta1.0588
Data delayed at least 15 minutes, as of Sep 20 2024 11:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3415265
Total Receivables, Net1,116938628
Total Inventory360220497
Prepaid expenses5721--
Other current assets, total2544323
Total current assets1,5931,2381,712
Property, plant & equipment, net1,6961,6861,694
Goodwill, net------
Intangibles, net2.660.891.01
Long term investments0.260.1438
Note receivable - long term20144.81
Other long term assets3537--
Total assets3,4353,0353,525
LIABILITIES
Accounts payable1,6271,4871,916
Accrued expenses75142--
Notes payable/short-term debt150132132
Current portion long-term debt/capital leases156527563
Other current liabilities, total133912987
Total current liabilities2,1413,2003,598
Total long term debt8592441
Total debt1,165683736
Deferred income tax------
Minority interest------
Other liabilities, total155139121
Total liabilities3,1563,3633,760
SHAREHOLDERS EQUITY
Common stock327327327
Additional paid-in capital1,0851,022--
Retained earnings (accumulated deficit)(1135)(1680)(561)
Treasury stock - common------
Unrealized gain (loss)01.17--
Other equity, total1.671.66--
Total equity279(328)(234)
Total liabilities & shareholders' equity3,4353,0353,525
Total common shares outstanding333333
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.